Securities Lawsuit Filed Against Rocket Pharmaceuticals, Inc.

Strategic Insights -

A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) on behalf of shareholders who allegedly suffered losses due to alleged securities fraud. The lawsuit claims that the company provided false and misleading statements about its RP-A501 clinical trial protocol and safety, causing investors to purchase securities at artificially inflated prices. The lawsuit seeks to recover losses for shareholders who were affected by the alleged fraud between February 27, 2025, and May 26, 2025.

Key Takeaways:

  • The lawsuit alleges that Rocket Pharmaceuticals provided false and misleading statements about the safety and clinical trial protocol of its RP-A501 program.
  • The company allegedly concealed material adverse facts concerning the true state of RP-A501's safety, including the risk of Serious Adverse Events (SAEs), including death of participants enrolled in the study.
  • Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.
  • The company made no attempt to alert investors or the public to the change in the protocol until after a SAE occurred, which resulted in the FDA placing a clinical hold on the RP-A501 Phase 2 pivotal study.
  • On May 27, 2025, the price of Rocket's common stock declined dramatically, falling 37% in a single trading day.
  • The lawsuit seeks to recover losses for shareholders who were affected by the alleged fraud between February 27, 2025, and May 26, 2025.
  • Levi & Korsinsky, a nationally-recognized securities litigation firm, is representing the plaintiffs in the case.

Statistics:

  • The lawsuit alleges that Rocket Pharmaceuticals provided false and misleading statements about the safety and clinical trial protocol of its RP-A501 program.
  • The company's stock price fell 37% in a single trading day on May 27, 2025, from a closing market price of $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025.
  • The lawsuit seeks to recover losses for shareholders who were affected by the alleged fraud between February 27, 2025, and May 26, 2025.

Sources:

  • Newsfile Corp. - July 21, 2025
  • Rocket Pharmaceuticals, Inc. investor call transcript (date not specified)
  • Case details: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=157425&wire=5